Department of Immunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
Department of Immunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
Thromb Res. 2022 May;213 Suppl 1:S46-S50. doi: 10.1016/j.thromres.2022.01.019. Epub 2022 May 26.
In malignant diseases, the development of a systemic hypercoagulable state is the consequence of the procoagulant activity of cancer cells on the hemostatic system and based on this close relationship, alterations in the levels of hemostatic biomarkers and/or biomarkers of blood clotting activation are under investigation as a potential tool in predicting for different cancer outcomes. Today, breast cancer remains the most common tumor and the second cause of mortality for cancer in women. There is still a need for novel biomarkers for making a diagnosis at a very early stage of disease and for the classification of individuals at different risks of disease recurrence or progression. In this review, we will discuss the pathogenesis of the thrombophilic state in breast cancer patients and its interconnection with the mechanisms of malignant progression, and report on the latest results from the HYPERCAN study in the context of hemostatic biomarker development in the breast cancer setting.
在恶性疾病中，全身性高凝状态的发展是癌细胞对止血系统的促凝活性的结果，基于这种密切关系，止血生物标志物和/或血栓形成激活标志物水平的改变被作为预测不同癌症结局的潜在工具进行研究。今天，乳腺癌仍然是最常见的肿瘤，也是女性癌症死亡的第二大原因。仍然需要新的生物标志物来在疾病的早期阶段进行诊断，以及对不同疾病复发或进展风险的个体进行分类。在这篇综述中，我们将讨论乳腺癌患者血栓形成状态的发病机制及其与恶性进展机制的相互关系，并报告 HYPERCAN 研究在乳腺癌环境中止血生物标志物开发方面的最新结果。
